2019
DOI: 10.1016/j.jcjo.2018.06.013
|View full text |Cite
|
Sign up to set email alerts
|

Ethambutol-induced optic neuropathy in renal disorder: a clinico-electrophysiological study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
8
0

Year Published

2019
2019
2023
2023

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 16 publications
(8 citation statements)
references
References 13 publications
0
8
0
Order By: Relevance
“…Furthermore, the damages to this sheath result in progressive axonal degeneration [27]. In this condition, ethambutol affects either the axonal or preaxial parts of the optic nerves by the demyelination process, primarily observed in the optic nerves and chiasma [4]. Consequently, it is probable that EMB binds to the optic chiasm with high affinity and causes bitemporal visual field abnormalities, which express themselves as toxic symptoms in the eyes [28].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Furthermore, the damages to this sheath result in progressive axonal degeneration [27]. In this condition, ethambutol affects either the axonal or preaxial parts of the optic nerves by the demyelination process, primarily observed in the optic nerves and chiasma [4]. Consequently, it is probable that EMB binds to the optic chiasm with high affinity and causes bitemporal visual field abnormalities, which express themselves as toxic symptoms in the eyes [28].…”
Section: Discussionmentioning
confidence: 99%
“…In a 10-year survey of 4.803 patients newly diagnosed with tuberculosis, it was reported that approximately 1.29% of them developed a case of ethambutol optic neuropathy [4]. Ethambutol has been shown to cause bulbar and retrobulbar neuritis, generally due to visual impairment with painless, subacute, symmetrical, and progressive symptoms.…”
Section: Introductionmentioning
confidence: 99%
“…Ocular side effects are believed to be dose-dependent, with most patients developing neuropathy at 60–100 mg/kg/day, although this is possible even at ≤15 mg/kg/day [ 146 ]. In addition, patients with kidney disease should not be treated with ethambutol, as this drug is mainly excreted via the kidneys and accumulates in the body when the kidney disease is present [ 147 ]. Discontinuation of the drug usually results in visual improvement [ 126 , 148 ], although some reports indicate that visual disability persists [ 149 , 150 ], as well as progressive structural damage in the absence of clinical symptoms [ 151 ].…”
Section: Treatment Optionsmentioning
confidence: 99%
“…In all these cases, it was identified that after ethambutol was discontinued, renal function recovered and no long-term renal dysfunction occurred 17 . In the process within the body, about 65% to 80% of ethambutol consumed will be excreted unchanged through the urine after passing through the kidneys, this condition proceed an increase in serum ethambutol levels causing its half-life also increases (about 7 to 15 hours in patients with stage renal failure) compared to 4 hours in normal people, therefore the toxicity due to the drug either increases 19 . Administration of isoniazid, pyrazinamide, rifampicin and of course ethambutol as antituberculosis drugs causes renal impairment and dysfunction due to involvement of these organs in the excretion of metabolites and active metabolites of these drugs.…”
Section: Toxicity Of Ethambutol On Renal Tissuementioning
confidence: 99%